Journal of Biological Chemistry · 2001 · 35 citations · 27 references
Life SciencesGeneticsMolecular GeneticsGene ExpressionGene RegulationTransgenic Animal ModelsConditional Transgenic ModelsGene Expression RegulationInducible Gene Expression SystemsTransgene Expression ControlTransgenesis StrategiesTransgenic Animal TechnologyConditional Gene ExpressionConditional Gene Expression ModelsTetracycline-inducible Gene ExpressionTetracycline-regulated Gene ExpressionTissue-specific ExpressionTransgenic AnimalsTransgenic MiceTransgenic Mouse Models
Adaptive epigenetic changes and toxicity often accompany constitutive expression of a transgene or knockout of an endogenous gene in mice. These considerations potentially limit the usefulness of transgenic technology in studying the in vivofunctions of a gene. Using conditional gene expression technology, it is possible to override such restrictions to achieve temporal and tissue-specific manipulation of gene expression in vivo. Based on the tetracycline regulatory system, we established a binary transgenic model in which the conditional expression of two transgenes, SV40 T antigen (TAg) and lacZ, can be tightly regulated in the liver by administration of tetracycline. The mouse albumin or mouse major urinary protein promoter was used to achieve liver-specific expression of the tetracycline-responsive transcriptional activator (tTA) in one set of transgenic mice. These mice were crossed with transgenic mice carrying either TAg orlacZ under the control of the tTA-regulated promoter. Analyses of mice transgenic for both tTA and TAg (or lacZ) revealed that the liver-specific expression of the transgenes could be suppressed to undetectable levels and regulated in a reversible fashion by tetracycline administration and withdrawal. Mice with tTA and TAg transgenes developed hepatocellular adenomas and hyperplasia that could be prevented by continuous tetracycline administration. Our report demonstrates the value of this binary transgenic model in studying the physiological functions of any potential genes of interest in a liver-specific manner. Adaptive epigenetic changes and toxicity often accompany constitutive expression of a transgene or knockout of an endogenous gene in mice. These considerations potentially limit the usefulness of transgenic technology in studying the in vivofunctions of a gene. Using conditional gene expression technology, it is possible to override such restrictions to achieve temporal and tissue-specific manipulation of gene expression in vivo. Based on the tetracycline regulatory system, we established a binary transgenic model in which the conditional expression of two transgenes, SV40 T antigen (TAg) and lacZ, can be tightly regulated in the liver by administration of tetracycline. The mouse albumin or mouse major urinary protein promoter was used to achieve liver-specific expression of the tetracycline-responsive transcriptional activator (tTA) in one set of transgenic mice. These mice were crossed with transgenic mice carrying either TAg orlacZ under the control of the tTA-regulated promoter. Analyses of mice transgenic for both tTA and TAg (or lacZ) revealed that the liver-specific expression of the transgenes could be suppressed to undetectable levels and regulated in a reversible fashion by tetracycline administration and withdrawal. Mice with tTA and TAg transgenes developed hepatocellular adenomas and hyperplasia that could be prevented by continuous tetracycline administration. Our report demonstrates the value of this binary transgenic model in studying the physiological functions of any potential genes of interest in a liver-specific manner. Transgenic mouse models have been used widely to study gene expression under in vivo physiological conditions. With tissue-specific promoters, it is possible to target gene expression exclusively in a specific tissue such as liver. However, constitutive expression of a transgene, especially if it deleteriously affects the tissues to which it is targeted, often results in prenatal or postnatal death or causes a variety of compensatory changes (1Kranias E.G. Annu. Rev. Physiol... 2000; 62: 965-969Google Scholar) in the overall gene expression pattern of the tissue. These changes could result in unexpected phenotypes that may not reflect the true biological functions of the transgene (2Sigmund C.D. Arterioscler. Thromb. Vasc. Biol... 2000; 20: 1425-1429Google Scholar, 3Jamieson B.D. Zack J.A. AIDS.. 1999; 13: S5-S11Google Scholar, 4Gossen M. Freundlieb S. Bender G. Muller G. Hillen W. Bujard H. Science.. 1995; 268: 1766-1769Google Scholar, 5Hennighausen L. Wall R.J. Tillmann U. Li M. Furth P.A. J. Cell. Biochem... 1995; 59: 463-472Google Scholar). In certain situations, the transgene is silenced by epigenetic events such as methylation because of its adverse effects on the cells (2Sigmund C.D. Arterioscler. Thromb. Vasc. Biol... 2000; 20: 1425-1429Google Scholar, 6Sutherland H.G. Kearns M. Morgan H.D. Headley A.P. Morris C. Martin D.I. Whitelaw E. Mamm. Genome.. 2000; 11: 347-355Google Scholar). Furthermore, the transgene behaves as a self-antigen, inducing negative selection of reactive T cells in the thymus and causing the animals to become immunologically tolerant to the transgene. Therefore, the immunologic response to the transgene cannot be easily studied without special manipulation. This aspect is particularly relevant in models of autoimmune or viral disease. To circumvent these problems, it is necessary to develop a system by which the expression of a transgene can be induced at desired time points and otherwise be kept completely silent for an extended period of time. Such a model may also allow a viral or self-antigen to escape the thymic selection process so the immunologic response can be studied. The use of inducible promoters, such as heat shock, metallothionein, and murine mammary tumor virus promoters, that can be regulated by temperature, zinc, or dexamethasone is frequently associated with a high basal level of expression, a less than impressive induction of the transgene, a relative lack of specificity, and a possible toxicity of the induction method (3Jamieson B.D. Zack J.A. AIDS.. 1999; 13: S5-S11Google Scholar, 4Gossen M. Freundlieb S. Bender G. Muller G. Hillen W. Bujard H. Science.. 1995; 268: 1766-1769Google Scholar, 7Agha-Mohammadi S. Lotze M.T. J. Clin. Invest... 2000; 105: 1177-1183Google Scholar). Conditional gene expression in vivo has been achieved using a variety of model systems. One of them takes advantage of thecre-lox recombination system by which a transgene can be activated and an endogenous gene deleted in a tissue-specific and time-dependent manner (8Sauer B. Methods.. 1998; 14: 381-392Google Scholar). However, this system requires the exogenous delivery of the cre gene (usually by an adeno- or retrovirus), and the induction is irreversible. Recently several drug- or ligand-inducible systems have been developed in vitro and, to some extent, in vivo (7Agha-Mohammadi S. Lotze M.T. J. Clin. Invest... 2000; 105: 1177-1183Google Scholar). These systems involve the use of a chimeric transcriptional activator that reversibly activates a target gene in response to the administration of the inducing agent. One of the systems that uses the intrinsic properties of the Escherichia coli tetracycline resistance operon has been applied widely to the generation of cell lines with tightly regulated gene expression in response to tetracycline (4Gossen M. Freundlieb S. Bender G. Muller G. Hillen W. Bujard H. Science.. 1995; 268: 1766-1769Google Scholar). This system has also been applied to the transgenic models of lymphoid and salivary development (5Hennighausen L. Wall R.J. Tillmann U. Li M. Furth P.A. J. Cell. Biochem... 1995; 59: 463-472Google Scholar), but no such model has been reported for liver-specific expression. In this study, we developed a binary transgenic mouse model that permits the tight control of transgene expression in a temporal and liver-specific fashion by tetracycline (the tetracycline-repressed regulatable system). We evaluated the efficiency of this system in transgenic mouse strains carrying one of two reporter genes, one coding for SV40 T antigen (TAg)1 and the other for β-galactosidase (lacZ), and the tetracycline-responsive transcriptional activator (tTA) under the control of liver-specific promoter of mouse albumin (Alb) (9Sandgren E.P. Quaife C.J. Pinkert C.A. Palmiter R.D. Brinster R.L. Oncogene.. 1989; 4: 715-724Google Scholar, 10Shiota G. Rhoads D.B. Wang T.C. Nakamura T. Schmidt E.V. Proc. Natl. Acad. Sci. U. S. A... 1992; 89: 373-377Google Scholar) or mouse major urinary protein (MUP) (11Held W.A. Mullins J.J. Kuhn N.J. Gallagher J.F. Gu G.D. Gross K.W. EMBO J... 1989; 8: 183-191Google Scholar, 12Derman E. Proc. Natl. Acad. Sci. U. S. A... 1981; 78: 5425-5429Google Scholar). tTA, in the absence of tetracycline, activates the reporter genes through binding to the reporter promoter sequence. The transgenes containing tTA under the control of the mouse albumin (Alb-tTA) or mouse major urinary protein (MUP-tTA) promoter were constructed (see Fig. 1 A). For construction of the Alb-tTA transgene, theEcoRI-BamHI fragment containing the tTA sequence from pUHD15.1 (22Gossen M. Bujard H. Proc. Natl. Acad. Sci. U. S. A... 1992; 89: 5547-5551Google Scholar) was cloned into the EcoRI andBamHI sites of the pBSIIKS+ vector (Stratagene). The tTA fragment released by digestion of the resulting plasmid withNotI and XhoI was inserted into the pGEMAlbSVtpA vector (33Kawamura T. Furusaka A. Koziel M. Chung R.T. Wang T.C. Schmidt E.V. Liang T.J. Hepatology.. 1997; 25: 1014-1021Google Scholar). The resulting construct was digested with NheI and NsiI sites to generate the Alb-tTA transgene (∼4.5 kilobase pairs). The MUP-tTA transgenic construct was generated the following way. The PstI-KpnI fragment containing the MUP promoter from MUPII (11Held W.A. Mullins J.J. Kuhn N.J. Gallagher J.F. Gu G.D. Gross K.W. EMBO J... 1989; 8: 183-191Google Scholar) was inserted into the NsiI and KpnI sites of pSVSPORT1 (Life Technologies, Inc.), replacing the SV40 promoter. The EcoRI-HpaI fragment containing tTA and SV40tIVSpA from pUHD15.1 was inserted into the SalI (treated with Klenow for blunt end) andEcoRI sites of the previous construct. The resulting plasmid was then digested with ClaI and MluI to generate the MUP-tTA transgenic fragment (∼4.0 kilobase pairs). These transgenes were introduced into fertilized eggs of FVB/n mice using standard transgenic techniques (13Hogan B. Constantini F. Lacy E. Manipulating the Mouse Embryo: A Laboratory Manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY1994Google Scholar). Mice transgenic for SV40 T antigen (tetO-TAg; from Shimon Efrat, Albert Einstein College of Medicine, Bronx, NY) (14Efrat S. Fusco-DeMane D. Lemberg H. al Emran O. Wang X. Proc. Natl. Acad. Sci. U. S. A... 1995; 92: 3576-3580Google Scholar) or β-galactosidase (lacZ; from the Jackson Laboratory, Bar Harbor, ME) (15Furth P.A. St. Onge L. Boger H. Gruss P. Gossen M. Kistner A. Bujard H. Hennighausen L. Proc. Natl. Acad. Sci. U. S. A... 1994; 91: 9302-9306Google Scholar) linked to the cytomegalovirus minimal promoter fused to the tTA-binding sequences (tetO) have been described previously. Genomic DNA isolated from tail clips of the offspring was used for genotyping. Genotyping of the Alb-tTA and MUP-tTA transgenic mice was performed using standard Southern blotting, and genotyping of the TAg mice was performed using the polymerase chain reaction (PCR) with TAg-specific primers (sense, 5′-GGA ATA GTC ACC ATG AAT GAG TAC AG-3′; and antisense, 5′-GGA CAA ACC ACA ACT AGA ATG CAG TG-3′). Slow-release tetracycline pellets (Innovative Research of America, Sarasota, FL) were implanted subcutaneously in the shoulder regions of mice using a trochar as described by the manufacturer. These pellets release 0.7 mg of tetracycline hydrochloride/day for 21 days. As negative controls, placebo tablets obtained from the same manufacturer were similarly implanted. Expression of the transgene was measured on day 20. A group of mice were killed and analyzed for their transgene expression on day 28 (7 days after the dissolution of the tetracycline pellets) to evaluate the reversibility of the transgene expression. 100 mg of liver or spleen tissue from the transgenic animals was homogenized in buffer containing 1% Nonidet P-40, 1% sodium deoxycholate, 1% SDS, 150 mmsodium chloride, 10 mm sodium phosphate, 2 mmEDTA, 50 mm sodium fluoride, and protease inhibitor mixture (Pefabloc SC, Roche Molecular Biochemicals) at a concentration of 1 mg/ml. Homogenates were centrifuged at 15,000 × g for 20 min at 4 °C, and the supernatants were collected. Total protein concentrations of the lysates were measured using a Coomassie Plus protein assay reagent kit (Pierce). Total RNAs from liver, spleen, brain, tongue, kidney, lung, heart, ovary, skin, and skeletal muscle were isolated using the Ultraspec-II RNA isolation reagent (Biotecx Laboratories, 100 mg of tissue was homogenized using a in 1 of Ultraspec-II RNA isolation The RNA was with and in T antigen was by using mouse and as the Laboratories, with a kit The level of was as an protein was performed using the system kit (Life Technologies, of RNA was with TAg-specific and the was to 10 using The mixture was at for 10 of the mixture was to the and the reaction was at 50 for 1 and by at for 1 of was for an 20 min at was by a standard one at for 4 at for 1 for 1 and for and a at for were on 1% and analyzed by Southern using TAg in the liver or spleen was measured using the β-galactosidase kit 100 mg of liver or spleen tissue was homogenized in 1 of containing 10 of a of 1 of and 100 of protease inhibitor mixture Roche Molecular from a containing one in 1 of The protein concentration of the was and 100 of was used for of β-galactosidase β-galactosidase was used as a and liver from mice was used as a negative The reaction mixture containing was measured using a and the results of the β-galactosidase were as of the Alb-tTA and were to tetracycline or placebo for a period of These mice were killed at the of the and other were for any A of tissue was in and were were with standard and evaluated for any Alb-tTA and and MUP-tTA and transgenic lines were Expression of tTA could be by in the from lines not The animals of tTA were crossed with the or mice to generate or transgenic mice for the was generated by Alb-tTA mice with and was generated by Alb-tTA mice with mice. The mice were generated the same way. and lines and were generated by MUP-tTA with obtained from were into on the animals both tTA and TAg tTA and TAg 1 The two were used as for the binary transgenic system in response to tetracycline administration. In one tetracycline the a and the tetracycline by days of tetracycline withdrawal. The for the group was to evaluate the reversibility of transgene expression by tetracycline To the tissue-specific of the transgene by tetracycline, we analyzed the and other the was for the generation of mice. The expression of transgene was by β-galactosidase the TAg mice described were analyzed for TAg expression in the liver, spleen, brain, tongue, kidney, lung, heart, ovary, skin, and skeletal Fig. 2 the levels of TAg expression in the and of the and mice and mice. TAg expression was in the liver and not in the for TAg revealed a absence of TAg expression in the liver not In these TAg expression was completely in the liver by tetracycline of the mice. In animals after days of tetracycline TAg expression to a level with the This level may be to a of the tetracycline from the a time of tetracycline release from the implanted The transgenic mice or were completely negative for TAg expression under the that the binary of this transgenic model for gene expression. TAg expression could be in the liver and not in the other that the expression is tightly regulated in the tissue. these results that a tightly liver-specific gene expression by tetracycline administration can be achieved in this transgenic However, it is to that were in the levels of TAg expression the mouse In lines and of the animals any level of TAg not To this transgenic system can be used to the conditional expression of any transgene, we evaluated the expression of the reporter gene using the same Fig. the levels expression in from these The animals from and a tight of expression in the liver by tetracycline, to the results obtained with the TAg lines not any protein in the absence of tetracycline, which is to the results obtained with the TAg This could be to a of in the of the to the system, gene expression was to the liver and was not in the of tetracycline in the gene expression in the liver. These the that gene expression can be with any gene of the of TAg expression of TAg or in transgenic mouse or was generated by Alb-tTA mice with mice. or was generated by Alb-tTA mice or mice. lines and were generated similarly by the MUP-tTA mice with mice. of the offspring were for both tTA and TAg or TAg or or tTA Mice with were implanted with either tetracycline or placebo A group of animals was with tetracycline, and analyzed 1 after of the tetracycline group at and animals with TAg or animals that to TAg or in a or was generated by Alb-tTA mice with mice. or was generated by Alb-tTA mice or mice. lines and were generated similarly by the MUP-tTA mice with mice. of the offspring were for both tTA and TAg or TAg or or tTA Mice with were implanted with either tetracycline or placebo A group of animals was with tetracycline, and analyzed 1 after of the tetracycline group at and animals with TAg or animals that to TAg or To is a level expression of the transgene under suppressed that is the limit of the protein method RNA was isolated from and tTA and TAg with or without tetracycline and to can as as of TAg which to less than one of RNA for to and is than The results of the of these RNA in in the absence of TAg with the placebo group The tetracycline group also levels of TAg of the of the tetracycline Furthermore, the absence of TAg in the TAg mice is with the that this transgene, in the absence of tTA, is completely is that constitutive expression of TAg in transgenic mouse models is 4 of and animals from were to tetracycline or placebo for a period of and Gross of the and skeletal of the animals was of was in of animals that were One of them a liver revealed hepatocellular with of and of tissues to the and The the were with and and or or were The other two mice of and one of them a These as the and were in of the liver changes to of the described In of the animals developed any of tumor in the liver as revealed by and In were to the liver which the that this regulatable system can be in a time-dependent and tissue-specific manner. other without of is possible that may have but in the absence of TAg expression, it is of tumor induction by tetracycline of mice with liver and animals from were with tetracycline or placebo for a period of and and other were for both changes and other than the liver in mice. tetracycline by 1 of tetracycline withdrawal. in a and animals from were with tetracycline or placebo for a period of and and other were for both changes and other than the liver in mice. tetracycline by 1 of tetracycline withdrawal. In this study, we developed a binary transgenic system in which the E. coli tetracycline was to achieve a tightly liver-specific gene expression in vivo. The liver-specific expression was using a liver-specific promoter (the mouse albumin or mouse major urinary protein to the tTA in one transgenic the other transgenic the reporter gene TAg or lacZ) under the control of to which tTA, in the absence of tetracycline, and Analyses of the transgenic mice that two of the Alb-tTA lines and one of the two MUP-tTA lines the of conditional expression in the liver. The expression of both reporter transgenes could be completely suppressed by tetracycline such a could be of tetracycline. The biological of this system was by the study of the TAg in which the transgenic animals developed liver in the absence of tetracycline, and the group liver SV40 T antigen has been to be in transgenic mice O. J. Scholar, M. M. A. P. A. J. Scholar, E.P. Brinster R.L. Scholar, B. 1989; Scholar). expression of TAg in the liver to and development of liver by of O. T. L. S. J. Scholar). we have not performed a study of tumor of mice in the absence of continuous tetracycline developed and hyperplasia at of The less potential of TAg in model a level of TAg expression than in other TAg transgenic mouse In a study by D. Li M. S. G. Wall R.J. Furth P.A. Hennighausen L. Science.. Scholar), the expression of TAg was to the salivary of mice. These mice developed hyperplasia at 4 of tumor development could be by tetracycline administration at 4 but not at of However, it is not the time or the of the is for tumor In we not the time is for tumor by tetracycline. to these transgenic mouse models have been developed using the system in target tissues or Gossen and Bujard (22Gossen M. Bujard H. Proc. Natl. Acad. Sci. U. S. A... 1992; 89: 5547-5551Google Scholar) were to achieve gene expression in lymphoid and and J. Clin. Invest... 1994; Scholar) in In study, the liver activator protein promoter was used for liver-specific expression of reporter gene expression could be in several such as spleen, heart, brain, and liver under the induced A. Gossen M. F. J. C. H. Bujard H. Proc. Natl. Acad. Sci. U. S. A... Scholar). In these it is not one can achieve of the transgene by tetracycline administration with techniques such as conditional expression systems have been applied to the transgenic and knockout The one is thecre-lox system (8Sauer B. Methods.. 1998; 14: 381-392Google Scholar, L. 1998; Scholar). cre is often by an or vector to mice with transgene Proc. Natl. Acad. Sci. U. S. A... Scholar, T. 1997; 8: Scholar). one can achieve tissue-specific using a tissue-specific promoter to the recombination by is often and the of viral may have effects on the tissues T. C. A. J. H. M. M. J. 1998; Scholar). transgenic mice under the control of tissue-specific can the viral but the advantage of specific of conditional expression is In recombination is not the potential of an conditional expression systems regulatable by such as 1997; Scholar), D. Proc. Natl. Acad. Sci. U. S. A... Scholar), and T. S. J.F. T. T. F. M. Scholar) have been developed A system using the and protein to gene expression has been developed in transgenic mice C. D. E. P. 1999; Scholar). several of of induction of the transgene can be achieved in it is not the of used for induction any biological effects on the animals or the basal level expression of the transgene Furthermore, the of by in vivo the usefulness of this system C. D. E. P. 1999; Scholar). Our study has several biological it is possible the expression of a transgene completely silent in the liver and to its expression at any time in a reversible manner. This allow a of the true biological functions of any gene in the liver in the of the physiological or of the without other compensatory or epigenetic this model system can be applied to the of an endogenous gene in a time-dependent manner. For cre could be under the control of the system for specific knockout of a or an transgene could be to the expression of an endogenous gene in the liver. by completely the transgene the it is possible to the thymic selection process of a transgene as a self-antigen and to the immunologic to the transgene in the This can be applied to the study of or viral The is particularly for in which is no A previous study has reported the induction of the virus response using the system to the expression of the transgene in liver T. C. A. J. H. M. M. J. 1998; Scholar). However, the of a of cre by to the of the effects of an virus response in vivo. We that model system the for the study of any endogenous or exogenous genes and their with the system in the of viral or other of liver disease. We for St. for and Shimon for the mice. We J. for of the We also the for Research on and and the for of for some of the transgenic mice. SV40 T antigen tetracycline-responsive transcriptional activator albumin major urinary protein polymerase chain reaction chain reaction Conditional liver-specific expression of virus T antigen to regulatable development of in transgenic of be as
27
Transcriptional Activation by Tetracyclines in Mammalian Cells
Manfred Gossen, Sabine Freundlieb, Gabriele Bender et al. · Science · 1995 · 2.5K citations
Manipulating the mouse embryo: A laboratory manual
Martin Johnson · Trends in Genetics · 1986 · 2.3K citations
Veterinary Medicine, Cell Biology, Developmental Biology +12